JIM1 Cell Line

Cat. #151449

JIM1 Cell Line

Cat. #: 151449

Sub-type: Primary

Unit size: 1x10^6 cells / vial

Organism: Human

Tissue: Blood

Disease: Cancer

Model: Tumour line


This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.


Inventor: M.S. Hamilton

Institute: University of Birmingham

Tool Details

Tool Details


  • Name: JIM1 Cell Line
  • Cancer: Blood cancer
  • Cancers detailed: Human multiple myeloma
  • Research fields: Cancer;Drug development;Genetics
  • Tool sub type: Primary
  • Organism: Human
  • Gender: Female
  • Tissue: Blood
  • Disease: Cancer
  • Growth properties: Suspension
  • Model: Tumour line
  • Conditional: Yes
  • Description: JIM1 was established from plasma myeloma cells derived from pleural fluid of an advanced multiple myeloma patient, and is homoplastic with the cell line JIM3. It allows in vitro study and comparison of genetic instability in myeloma tumour lines and in vitro study of the effects of DNA repair deficiency in myeloma tumour lines. JIM1 shows typical plasma cell phenotype (CD38, PCA-1 8A and CD24 positive), deficient in DNA repair.
  • Production details: Derived from plasma myeloma cells from pleural fluid of advanced multiple myeloma female patient.
  • Additional notes: STR profiling showed that this cell line is of female origin
  • Cellosaurus id: CVCL_2532


  • Application notes: STR profiling showed that this cell line is of female origin


  • Format: Frozen
  • Growth medium: Dexter culture medium, consisting of Fischer's medium + 20% FCS +10-7 M hydrocortisone sodium succinate. Seed at 2-9 x 10 5 cells/cm3 5% CO2; 37?‚°C
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice


  • Brito et al. 2009. Haematologica. 94(1):78-86. PMID: 19059936.
  • MMSET deregulation affects cell cycle progression and adhesion regulons in t(4
  • 14) myeloma plasma cells.
  • Leone et al. 2008. Clin Cancer Res. 14(19):6033-41. PMID: 18829482.
  • Deletions of CDKN2C in multiple myeloma: biological and clinical implications.
  • Velangi et al. 2004. Carcinogenesis. 25(10):1795-803. PMID: 15142887.
  • DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma.
  • Hamilton et al. 19...